The positive results from PALOMA-2 and MONALEESA-2 indicate that the combination of letrozole and a CDK4/6 inhibitor is likely to become a major treatment option for first-line therapy of advanced, ER-positive, HER2-negative breast cancer in postmenopausal women. Here, ERBB2 is linked to breast cancer.